{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+B+-+Part+2&page=2",
    "query": {
      "intervention": "Treatment B - Part 2",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+B+-+Part+2&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T21:06:58.567Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06491550",
      "title": "A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "AZD4144- Part A",
          "type": "DRUG"
        },
        {
          "name": "Placebo- Part A",
          "type": "DRUG"
        },
        {
          "name": "AZD4144- Part B",
          "type": "DRUG"
        },
        {
          "name": "Placebo- Part B",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin and Furosemide- Part C",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin, Furosemide, and AZD4144 Part C",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 91,
      "start_date": "2024-07-15",
      "completion_date": "2025-06-11",
      "has_results": false,
      "last_update_posted_date": "2025-07-04",
      "last_synced_at": "2026-09-27T21:06:58.567Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Brooklyn, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Brooklyn",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06491550"
    },
    {
      "nct_id": "NCT04165343",
      "title": "Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on EXPLORER",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Non-Alcoholic Fatty Liver Disease (NAFLD)",
        "Nonalcoholic Steatohepatitis (NASH)"
      ],
      "interventions": [
        {
          "name": "Positron Emission Tomography (PET) on EXPLORER",
          "type": "RADIATION"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Echocardiogram and Electrocardiogram",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Blood test",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 81,
      "start_date": "2019-11-01",
      "completion_date": "2023-05-11",
      "has_results": false,
      "last_update_posted_date": "2023-09-01",
      "last_synced_at": "2026-09-27T21:06:58.567Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04165343"
    },
    {
      "nct_id": "NCT05708950",
      "title": "A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Solid Tumor",
        "Melanoma",
        "Carcinoma",
        "Sarcoma",
        "Lung Cancer",
        "Prostate Cancer",
        "Breast Cancer",
        "Colo-rectal Cancer",
        "Uterine Cancer",
        "Pancreatic Cancer",
        "Gastric Cancer",
        "Esophageal Cancer",
        "Thyroid Cancer",
        "Ovarian Cancer",
        "Kidney Cancer",
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "KVA12123 - Dose Escalation",
          "type": "DRUG"
        },
        {
          "name": "KVA12123 Plus Pembrolizumab - Dose Escalation",
          "type": "DRUG"
        },
        {
          "name": "KVA12123 - Dose Expansion",
          "type": "DRUG"
        },
        {
          "name": "KVA12123 Plus Pembrolizumab - Dose Expansion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kineta Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2023-03-03",
      "completion_date": "2025-12-18",
      "has_results": false,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-09-27T21:06:58.567Z",
      "location_count": 7,
      "location_summary": "Santa Monica, California • Denver, Colorado • Sarasota, Florida + 4 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05708950"
    },
    {
      "nct_id": "NCT07704580",
      "title": "Phase 1b/2 Study of IV Sarilumab in Adult With RA",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Sarilumab, SAR153191 SC",
          "type": "DRUG"
        },
        {
          "name": "Sarilumab, SAR153191 IV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2026-07-02",
      "completion_date": "2028-10-26",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-09-27T21:06:58.567Z",
      "location_count": 4,
      "location_summary": "Hollywood, Florida • Weston, Florida • Duncansville, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Weston",
          "state": "Florida"
        },
        {
          "city": "Duncansville",
          "state": "Pennsylvania"
        },
        {
          "city": "Plano",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07704580"
    },
    {
      "nct_id": "NCT01692262",
      "title": "Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castrate-Resistant Prostate Cancer (mCRPC),",
        "Efficacy,",
        "Safety and Tolerability,",
        "Pharmacokinetics,",
        "Pharmacodynamics,",
        "Tumour Response."
      ],
      "interventions": [
        {
          "name": "Intermittent dosing of AZD5363",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 59,
      "start_date": "2012-11",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-06-19",
      "last_synced_at": "2026-09-27T21:06:58.567Z",
      "location_count": 5,
      "location_summary": "Sarasota, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 2 more",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01692262"
    },
    {
      "nct_id": "NCT00750815",
      "title": "Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2008-09",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2014-01-20",
      "last_synced_at": "2026-09-27T21:06:58.567Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00750815"
    },
    {
      "nct_id": "NCT05254327",
      "title": "Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "BMX-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 118,
      "start_date": "2022-08-15",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-09-27T21:06:58.567Z",
      "location_count": 3,
      "location_summary": "Lexington, Kentucky • Omaha, Nebraska • San Antonio, Texas",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05254327"
    },
    {
      "nct_id": "NCT02244112",
      "title": "A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Non-Central Nervous System (CNS) Malignancies"
      ],
      "interventions": [
        {
          "name": "Oprozomib",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2014-08",
      "completion_date": "2019-07-10",
      "has_results": false,
      "last_update_posted_date": "2021-02-21",
      "last_synced_at": "2026-09-27T21:06:58.567Z",
      "location_count": 7,
      "location_summary": "Aurora, Colorado • Atlanta, Georgia • Detroit, Michigan + 4 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02244112"
    },
    {
      "nct_id": "NCT01287520",
      "title": "A Study of LY2090314 in Patients With Advanced or Metastatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer"
      ],
      "interventions": [
        {
          "name": "LY2090314",
          "type": "DRUG"
        },
        {
          "name": "pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "ranitidine",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "25 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2007-11",
      "completion_date": "2011-04",
      "has_results": true,
      "last_update_posted_date": "2019-02-25",
      "last_synced_at": "2026-09-27T21:06:58.567Z",
      "location_count": 2,
      "location_summary": "Tampa, Florida • Nashville, Tennessee",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01287520"
    },
    {
      "nct_id": "NCT04421820",
      "title": "BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Pancreatic Cancer",
        "Gastric Cancers",
        "Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "BOLD-100 +/- FOLFOX Chemotherapy (Arm VII)",
          "type": "DRUG"
        },
        {
          "name": "BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bold Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2020-08-28",
      "completion_date": "2026-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-09-27T21:06:58.567Z",
      "location_count": 2,
      "location_summary": "Santa Monica, California • Tampa, Florida",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04421820"
    }
  ]
}